We performed a prospective trial investigating the feasibility of a double lumen port access in 26 patients with hematological malignancies or solid tumors receiving either standard conditioning (n ‫؍‬ 9, median age 49 years (range 19-65)) or dose-reduced conditioning (n ‫؍‬ 17, median age 56 years (range 35-66)) followed by allogeneic blood stem cell transplantation. The port system was implanted within 3 months (n ‫؍‬ 20, range 7-91 days) before transplantation or as indicated at different time points after transplantation (n ‫؍‬ 6, range 28-680 days). Most infusions, including the graft itself and all blood drawings, were performed via the port. Over a cumulative duration of 5622 days (1310 days after standard conditioning (range 56-349) and 4431 days after dose-reduced conditioning (range 49-489)) two port systems of patients receiving standard conditioning were removed due to early postimplantation pocket infection on day 6 and 8 after insertion, respectively. In the dose-reduced conditioning group only one late removal (day 287) of a port was required. Most of the patients in both groups reported less pain and a higher degree of comfort compared to peripheral or central venipuncture. The use of double lumen port access during conditioning and in an outpatient setting after allogeneic hemopoietic stem cell transplantation is feasible and advantageous for both patient and medical staff. Implantation several weeks before the start of conditioning might help in avoiding early infectious complications after conventional myeloablative conditioning. Bone Marrow Transplantation (2001) 28, 1067-1072. Keywords: double lumen port; allogeneic; dose-reduced conditioning Dose-reduced conditioning (DRC) followed by allogeneic stem cell transplantation (SCT) is increasingly performed
in patients with hematological malignancies not eligible for conventional myeloablative procedures. 1 Nevertheless, prolonged and often multi-line central venous access is needed for the concomitant administration of antineoplastic agents, antibiotics, blood products, immunosuppressive and antiviral drugs, and other agents. Conventional Hickman catheters or disposable central lines are routinely used in patients receiving allogeneic cell therapy. They are associated with restrictions 2 in patient activities, and complications such as infections and thrombosis are frequent. [3] [4] [5] [6] [7] [8] [9] Port systems have the advantage of easy maintenance and have been successfully used even in patients receiving high-dose chemotherapy and autologous stem cell transplantation. 10 However, because of a greater demand for infusions and blood drawings during the course of treatment, single lumen port systems are generally not feasible for this group of patients. Double lumen port systems (DLPS) might be of interest for patients receiving allogeneic SCT as they also allow for a broader range of activities and fewer restrictions. To our knowledge no studies thus far have prospectively investigated the usefulness of a double lumen port device in these patients. Due to its separate chambers, a DLPS allows regular blood drawings and the administration of otherwise incompatible drugs. We prospectively investigated such a device in patients receiving allogeneic SCT after either standard or dose-reduced conditioning. Results indicate that this approach is feasible, especially in patients receiving dose-reduced conditioning for allogeneic SCT.
Patients and methods
Twenty-six patients with hematological malignancies or solid tumors received a DLPS either prior to or after standard (group A, n = 9) or dose-reduced conditioning (group B, n = 17). Patient characteristics are summarized in Table 1 . Seven patients were diagnosed with acute myeloid leukemia, three with ALL, six with CLL/NHL, four with MDS, four with Ph+ chronic myeloid leukemia, one with Hodgkin's disease (HD), and one with renal cell cancer (RCC). The median age was 49 years (range 19-65) in group A/SC and 56 years (range 35-66) in group B/DRC.
Indication for application of a DLPS after transplant was
Bone Marrow Transplantation the anticipated needs for prolonged venous access (ie parenteral nutrition, antibiotics, chemotherapy) either due to relapse (n = 3) or chronic GVHD (n = 3). Implantation required normal coagulation tests, a neutrophil count Ͼ500/l and a platelet count above 50 000/l. All devices were implanted in the operating room under sterile conditions and radiological control by four different operators (TI, MS, JFR, UP). The catheters were inserted under local anesthesia through direct puncture of the subclavian vein using the Seldinger technique. The catheter was tunneled subcutaneously via an incision below the puncture site. After preparation of the port pocket, the catheter was connected to the DLPS and fixed by two sutures on the fascia of the M. pectoralis. Function of the system was checked and the incision was closed in layers. A chest X-ray was always obtained to document correct positioning. All patients received the same type of port (7 Fr dual-lumen, open-ended (1.1 mm i.d.) Rosenblatt Dual Slim Port, BardPort, Salt Lake City, UT, USA) as shown in Figure 1 . The two self-sealing silicone puncture sites are round, with a 11-mm diameter and separated by a ridge to allow easy localization by palpation. The lumen size allows both rapid infusions (500 ml/h) and easy withdrawal of blood.
Figure 1
The DLPS used in this study compared to a conventional single lumen port-access. /kg BW). GVHD prophylaxis consisted of CsA and methotrexate (10 mg/m 2 days 1, 3, 6) in three patients, CsA plus mycophenolate mofetil (MMF) at 34 mg/kg BW/day i.v. or 4 × 500 mg p.o. in five, and CsA alone in one patient. The CsA dose was adjusted to achieve trough blood levels of 200-300 ng/ml. The DLPS was implanted a median of 33 days (range 8-91) prior to allogeneic transplantation in six patients, and a median of 83 days (range 56-142) after allogeneic transplantation in three patients.
Group A/SC

Group B/DRC
Sixteen patients received DRC with either intravenous busulfan (3.3 mg/kg BW once daily i.v. for 2 days, total dose 6.6 mg/kg BW) or oral busulfan (8 The DLPS was implanted a median of 12 days (range 7-50 days) prior to allogeneic transplantation in 14 patients and a median of 120 days (range 28-680 days) after allogeneic transplantation in three patients.
Follow-up was continued until the device was removed or upon the patient's death. Complications were classified as early (intra and early postoperative) or late (occurring after first use of the device). Blood samples or wound swab for microbiological analyses were performed when clinically indicated, especially when fever occurred or the pocket of the port showed signs of inflammation. Infections were defined according to Press et al 9 as follows: (1) Tunnel infection: erythema, tenderness or induration along the subcutaneous tract of the catheter; (2) catheter-related bacteremia: a positive blood culture obtained from the port system in the absence of positive peripheral blood cultures; (3) port pocket infection: erythema, tenderness and induration around the port with culture-positive material. Thrombosis, if clinically suggested, was detected with Doppler-ultrasound, venography, or both. During the period of conditioning and until engraftment, all patients received 10 000 units of heparin/24 h intravenously. Subsequently, to maintain the patency of the DLPS, the system was rinsed with saline solution and blocked with heparin at least every 4 to 6 weeks.
In order to determine the tolerability of the system, all patients were asked the following: (1) how they tolerated the DLPS; (2) to compare the pain rate with a peripheral venipuncture or the insertion of a central venous line; and (3) whether they would accept the implantation of a DLPS again.
Results
Twenty-six devices were placed in 26 patients, and remained in place for a cumulative duration of 5622 days in situ (1310 days in group A (range 56-349) and 4431 days in group B (range 49-489)). Pre-implantation coagaulation tests were within the normal range in all patients. Six patients (DRC group n = 1, SC group n = 5) received platelet transfusions before implantation in order to increase platelet count up to 50 000/l. As shown in Table 2 , various post-transplant complications occurred in both groups including CMV reactivation, GVHD, relapse and graft failure requiring readmission to hospital and extended use of the DLPS in 18 patients. Table 2 Transplant-and port-related complications after allogeneic transplantation of both groups In the same patient the port device was explanted on day 294.
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SC (n = 9) DRC (n = 17) CMV-antigenemia 3 7 GVHD уII 7 13 Graft failure 1 1 Need of parenteral nutrition 9 11 Relapse 2 4 Death 4 5 Readmission to hospital 6 12 Early port-related complications Reversible hematoma 1 2 Late port-related complications Port-related thrombosis 1 0 Port leakage 0 1 Catheter occlusion (single lumen) 0 1 Port pocket or tunnel infection 2 a 0 Port-related bacteremia
Group A/SC
All necessary infusions including antibiotics, chemotherapy, nutrition, immunosuppressive drugs, and in most cases, the infusion of stem cells, as well as all regular blood drawings were performed mostly in an outpatient setting via the port. In five patients, an additional central line was placed in order to provide sufficient venous access during the period of conditioning.
Early complications: One patient (with thrombocytopenia Ͻ50 000/l receiving a platelet transfusion before implantation) developed a reversible hematoma after implantation. No pneumothorax occurred.
Late complications:
No occlusions of the port catheters were observed. In one patient a port-related thrombosis of the subclavian vein was diagnosed 65 days after insertion. A port pocket infection occurred in two patients on days 6 and 8 after insertion, respectively. Both received the DLPS immediately prior to transplantation (Ͻ8 days). One of these patients was neutropenic (Ͻ1000/l) on the day of insertion, and the port pocket infection was caused by Staphylococcus epidermidis. The second patient's cultures remained negative. Both port systems were removed. No port-related deaths were observed. Two patients died due to pneumonia (aspergillus) and two due to progressive disease.
Quality of life:
As shown in Table 3 , all but two patients (discomfort while sleeping on the port side and during physical activity) tolerated the DLPS well with no restrictions in their routine daily life. All but two patients stated that they would again agree to the insertion of a port device. Most of the patients experienced less or comparable pain than venipuncture (less, n = 5; equivalent, n = 3; greater, n = 1). Pain and discomfort during insertion compared to central line was estimated to be equivalent in five and greater in two patients. Two out of nine patients had never received a central line before.
Group B/DRC
The DLPS were used as described in group A. No patients needed an additional central line. In one patient DLPS was electively removed (where it was no longer needed) one year after allogeneic transplantation.
Early complications: Two patients (one with thrombocytopenia Ͻ50 000/l receiving a platelet transfusion before implantation) experienced a reversible hematoma after implantation. No pneumothorax was observed.
Late complications: One patient experienced catheter leakage during the first use of the DLPS. The problem resolved with readaption of the catheter 2 days after insertion. An irreversible occlusion of one of the port catheters occurred in one patient 203 days after insertion. The same patient experienced a port-related febrile bacteremia caused by Staphylococcus epidermidis on day 287. The port was explanted and the postoperative course was uneventful. No port-related thromboses of the subclavian vein, and no port pocket infections were diagnosed. There were no portrelated deaths. Two patients died due to pneumonia (aspergillus and HHV 6, respectively) and three from progressive disease.
Quality of life:
As shown in Table 3 , all but two patients (mechanical discomfort during sleep on the port side and from seat belt pressure) tolerated the port system well without restriction of their routine daily life. All patients would again agree to the insertion of a port device. Most of the patients reported less or similar pain to that of venipuncture (less, n = 9; equivalent, n = 7; greater, n = 1). Pain and discomfort during insertion compared to central line insertion was estimated to be less in one, equivalent in five, and greater in two patients. Nine out of 17 patients had never received a central line before.
Discussion
Central venous access, especially during the time of conditioning, is always required in patients receiving allogeneic SCT. Most patients experience intensive chemotherapeutic pretreatment leading to occlusion of most peripheral veins. This situation makes a permanent vascular access device attractive. Hickman catheters are the device of choice for these patients, 4,11 because they allow for blood drawing and for infusion of parenteral nutrition, antibiotics, antiviral drugs and blood products. Since some data suggest that they have a higher complication rate compared to indwelling catheters in patients with hematological malignancies, 12 venous ports have been preferentially used in patients with solid tumors. 13, 14 Nevertheless port systems have been shown to provide stable venous access beyond day 100 15 with a rate of infection and thrombosis comparable to external vascular access devices even in patients with leukemia. 2, [16] [17] [18] [19] Ports were shown to provide longer failurefree function than Hickman and Broviac catheters. 15 The feasibility of prolonged and durable central venous access in a dog model of myeloablative BMT has been shown by Dennis et al. 20 While there are reports on single lumen ports in patients with leukemia, 21 no data on the prospective use of port devices in patients receiving allogeneic blood stem cell transplantation have been published. In the present study, we have shown the feasibility of using a DLPS in patients undergoing allogeneic SCT.
Catheter-related infection rates of 11-45% 17,22-24 have been reported in Hickman catheters and of 0-22% 17, 22, 25, 26 in patients with implantable port access. Given the high risk of prolonged neutropenia and the sustained immunosuppression in our patients, the infection rate was moderate and comparable to that observed in other studies. 12 The risk may be lowered if the port is implanted more than 4 weeks before transplantation. This agrees with other reports showing an increased risk of complications in patients where the port is first used within 2 weeks after placement as compared with those used later. 16 Those early infections did not occur in the DRC group, presumably due to the shorter period of absolute neutropenia observed with this regimen. 1 The occurrence of neutropenia does not seem to be a predictor for the incidence of access-related infection. 27 Based on our experience, a blood coagulation test without any pathological findings and a platelet count above 50 000/l independently of transfusions is recommended in order to prevent bleeding complications. Generally, the rate of complications is inversely related to the expertise of the operator involved and the experience, commitment, and training of the nursing staff responsible for the care and maintenance of the implanted catheter device. 16 We believe that these prerequisites were met at our institution since more than 600 port devices have been implanted over the last 5 years.
Given the increased risk of thrombosis after allogeneic BMT reported in the literature, 28 the rate of clinically diagnosed events observed in the present study was low, [12] [13] [14] [29] [30] [31] although we did not formally exclude asymptotic thrombosis by venography or Doppler of central veins. Although the graft was mostly infused via the port we do not recommend this procedure for fresh bone marrow with a higher viscosity than peripheral blood stem cells. In our experience the flow rate is very slow through the catheter and is associated with an increased risk of temporary occlusions.
Most patients in both groups reported less pain and a higher level of comfort than experienced with conventional venous access and the insertion of a central line. The DLPS used in this present study is very slim and normally does not affect any physical activity. Most of the patients were pretreated intensively and consequently had difficult peripheral veins. The frequent need for readmission of such patients after transplant requires stable and reliable venous access. One randomized trial showed no significant impact on quality of life associated with the use of ports compared to intermittent peripheral access. 32 In contrast to the present report, the patient population in that study consisted only of patients with solid tumors who had blood drawn also via peripheral phlebotomy. In our study all blood drawings were performed routinely via the DLPS, even in the outpatient setting thereby avoiding potential peripheral access problems.
A disadvantage of the port system is the initial price of the device ($500) compared to a standard Hickman catheter ($200). Additionally special needle sets are needed in order to get access to veins. This is in fact superceded by the long durability, cosmetic benefit and good tolerability of the DLPS.
In conclusion, the DLPS appears to be a reasonable and advantageous approach both for the patient and the medical staff either when implanted before or after allogeneic transplant. This might become especially relevant for older patients who are increasingly included in studies evaluating dose-reduced or non-myeloablative preparative regimens. The occasional need to place an additional central line and the higher infection rate in patients given standard intensity conditioning, however, clearly shows the limitations of this system. Further studies are warranted to determine the value of such devices in patients receiving allogeneic SCT.
